Cover Image
市場調查報告書

基因重組型人血液凝固第八凝血因子的中國市場

Investigation Report on Recombinant Human Coagulation Factor VIII in China, 2018-2022

出版商 China Research and Intelligence 商品編碼 332764
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
基因重組型人血液凝固第八凝血因子的中國市場 Investigation Report on Recombinant Human Coagulation Factor VIII in China, 2018-2022
出版日期: 2018年06月25日 內容資訊: 英文 30 Pages
簡介

本報告提供中國的基因重組型人血液凝固第八凝血因子市場規模與未來展望 (今後5年份),主要製藥公司及各劑型的市場佔有率,銷售價格等資訊。

第1章 基因重組型人血液凝固第八凝血因子的相關概念

  • 前兆
  • 中國國內的發病情形

第2 中國市場概況:基因重組型人血液凝固第八凝血因子市場

  • 藥物的相關專利及政府的認證情形
  • 主要製造商

第3章 中國國內的銷售趨勢 (過去5年份):基因重組型人血液凝固第八凝血因子市場

  • 銷售額 (銷售額)
    • 總銷售額
    • 在主要地區的銷售額
  • 銷售量
    • 整體銷售量
    • 在主要地區的銷售量
  • 各劑型的銷售額

第4章 主要廠商的市場佔有率 (過去5年份):中國的基因重組型人血液凝固第八凝血因子市場

  • 市場佔有率 (以金額為準)
  • 市場佔有率 (以數量為準)

第5章 與主要製造商參考價格:中國的基因重組型人血液凝固第八凝血因子市場

  • Bayer
    • 企業簡介
    • 基因重組型人血液凝固第八凝血因子的銷售額
    • 中國的平均銷售價格:基因重組型人血液凝固第八凝血因子
  • Baxalta
  • Wyeth

第6章 市場未來展望 (今後5年份):基因重組型人血液凝固第八凝血因子市場

  • 市場趨勢的影響要素的預測
  • 市場規模的預測
  • 市場發展趨勢的預測

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 1806296

There are more than 400,000 people with hemophilia in the world, Chinese surpassing 100,000. The registered hemophilia patients in China are less than 20,000, because most patients give up treatment due to the expensive medical expenses. Those who lack coagulation factor VIII account for 80% to 85% of the hemophilia A patients. Currently, there is no cure for hemophilia, treatment for which on the market are all alternatives. Coagulation factors are the main drugs.

In 1992, Baxter (Baxalta) publicized the first recombinant coagulation factor VIII. Because it has the same effects as natural coagulation factors without risks of blood-borne virus contamination, it is very popular in the market. The developed countries master mature technologies of recombinant coagulation factors. For example, recombinant coagulation factor VIII now has experienced four rounds of upgradation. The main manufacturers are Bayer, Baxalta, Wyeth, etc. By Jun. 2018, no domestic recombinant coagulation factor VIII has been launched. In May 2018, China's local biopharmaceutical company Beijing Tiantan Biological Products Co., Ltd. announced that its subsidiary Chengdu Rongsheng Pharmaceutical Co., Ltd. had received Approval Document for Clinical Trials of recombinant human coagulation factor VIII for injection issued by the CFDA.

Recombinant human coagulation factor VIII developed rapidly after entering China. Its annual sales increased from less than CNY 6 million in 2009 to CNY 300 million in 2017, and the CAGR reached 65.2% from 2009 to 2017. Currently, recombinant human coagulation factor VIII sold on the Chinese market is all imported from Bayer, Baxalta and Wyeth. Bayer secures the highest market share, which was close to 68% in 2017.

CRI forecasts that with the development of China's economy, patients with hemophilia are more able to pay medical expenses. It is expected that the market scale of recombinant human coagulation factor VIII in China will continue to increase from 2018 to 2022. After 2022, there is possibility that Chinese companies may launch recombinant human coagulation factor VIII.

Topics Covered:

  • Development of Recombinant Human Coagulation Factor VIII in China
  • Sales of Recombinant Human Coagulation Factor VIII in China
  • Sale price of Recombinant Human Coagulation Factor VIII in the Chinese market
  • Manufacturers of Recombinant Human Coagulation Factor VIII in the Chinese market
  • Research progress of Chinese companies on Recombinant Human Coagulation Factor VIII
  • Chinese market prospects on Recombinant Human Coagulation Factor VIII from 2018 to 2022

Table of Contents

1 Relevant Concepts of Recombinant Human Coagulation Factor VIII

  • 1.1 Indication
  • 1.2 Development in China

2 Chinese Market Overview of Recombinant Human Coagulation Factor VIII

  • 2.1 Patents and Government Approval on Drugs
  • 2.2 Major Manufacturers

3 Sales of Recombinant Human Coagulation Factor VIII in China, 2013-2017

  • 3.1 Sales Value
    • 3.1.1 Overall Sales Value
    • 3.1.2 Sales Value in Key Regions
  • 3.2 Sales Volume
    • 3.2.1 Overall Sales Volume
    • 3.2.2 Sales Volume in Key Regions
  • 3.3 Sales of Different Dosage Forms

4 Market Share of Major Manufacturers of Recombinant Human Coagulation Factor VIII in China, 2013-2017

  • 4.1 Market Share by Sales Value
  • 4.2 Market Share by Sales Volume

5 Major Manufacturers and Reference Sale Price of Recombinant Human Coagulation Factor VIII in Chinese Market, 2017-2018

  • 5.1 Bayer
    • 5.1.1 Enterprise Profile
    • 5.1.2 Sales of Bayer's Recombinant Human Coagulation Factor VIII
    • 5.1.3 Average Sale Price of Bayer's Recombinant Human Coagulation Factor VIII in Parts of China
  • 5.2 Baxalta
  • 5.3 Wyeth

6 Market Prospects of Recombinant Human Coagulation Factor VIII, 2018-2022

  • 6.1 Forecast on Factors Influencing Development
  • 6.2 Forecast on Market Size
  • 6.3 Forecast on Development Trend

Part of Charts

  • Chart Patents of Recombinant Human Coagulation Factor VIII in China
  • Chart Sales of Recombinant Human Coagulation Factor VIII in China
  • Chart Sales Value of Recombinant Human Coagulation Factor VIII in China, 2013-2017
  • Chart Sales Value of Recombinant Human Coagulation Factor VIII in Parts of China, 2013-2017
  • Chart Sales Volume of Recombinant Human Coagulation Factor VIII in China, 2013-2017
  • Chart Sales Volume of Recombinant Human Coagulation Factor VIII in Parts of China, 2013-2017
  • Chart Sales Value and Market Share of Bayer's Recombinant Human Coagulation Factor VIII in China, 2013-2017
  • Chart Sales Value and Market Share of Baxalta's Recombinant Human Coagulation Factor VIII in China, 2013-2017
  • Chart Sales Value and Market Share of Wyeth's Recombinant Human Coagulation Factor VIII in China, 2013-2017
  • Chart Sale Price of Bayer's Recombinant Human Coagulation Factor VIII in Some Chinese Cities, 2017-2018
  • Chart Sale Price of Baxalta's Recombinant Human Coagulation Factor VIII in Some Chinese Cities, 2017-2018
  • Chart Forecast on Sale Price of Recombinant Human Coagulation Factor VIII in China, 2018-2022
Back to Top